Chemical Approaches to Target Validation for Drug Resistant Pathogens (R01) | Apply Online

Opportunity Summary:

The National Institutes of Health (NIH) funding opportunity titled "Chemical Approaches to Target Validation for Drug Resistant Pathogens (R01)" (Funding Opportunity Number RFA-AI-11-004) was a discretionary grant program designed to support research that uses chemical biology approaches to strengthen and clarify biological target validation in the context of drug-resistant infectious diseases. Instead of prioritizing near-term medicinal chemistry or the direct discovery of therapeutic products, this announcement aimed to fund projects that build a deeper, more reliable understanding of which host or pathogen proteins truly matter for infection biology and can realistically serve as future drug targets. In practice, the emphasis was on using chemical tools to answer fundamental questions about microbial processes and host-pathogen interactions and to determine the biological activity of proteins from either the pathogen or the host, especially where those proteins may be poorly characterized or only predicted from genomic data.

A central theme of the opportunity was the use of chemical tools as probes for function, mechanism, and validation. That includes approaches where small molecules, chemical probes, or other chemistry-enabled strategies are used to perturb biological systems in a controlled way so researchers can observe cause-and-effect relationships. The expectation was that these kinds of studies would help establish a more solid foundation for later-stage work, such as broader chemical screening campaigns to find lead compounds, and would also support functional annotation of gene products, meaning the assignment of real biological roles to proteins that might be known only as sequences or hypothetical open reading frames. By focusing on target validation and functional understanding, the program was positioned to reduce the risk of downstream drug discovery by ensuring that future screens and development efforts are aimed at targets with demonstrated biological relevance.

The funding mechanism was the NIH R01 research project grant, which typically supports hypothesis-driven, investigator-initiated research within a defined scope and timeline. The overall estimated total funding for the announcement was $8,000,000, with an award ceiling listed as $750,000. The program did not require cost sharing or matching funds, which generally lowers barriers for applicants and allows budgets to be driven by scientific needs rather than institutional cost-share capacity. The announcement was posted and created on February 17, 2011, with an original and current closing date of June 15, 2011, and an archive date of July 16, 2011, indicating it was a time-limited solicitation rather than an ongoing open submission opportunity.

The opportunity fell under NIH activity areas associated with infectious disease and immune-related research, specifically CFDA numbers 93.855 (Allergy, Immunology and Transplantation Research) and 93.856 (Microbiology and Infectious Diseases Research). This aligns with the scientific focus on pathogens, host responses, and host-pathogen biology, particularly where antimicrobial resistance creates urgent unmet needs. While the title emphasizes "drug resistant pathogens," the program’s design makes clear that the immediate deliverable was not a drug candidate, but validated targets, clarified mechanisms, and chemical tools or strategies that can reliably link a protein or pathway to a meaningful phenotype relevant to infection.

Eligibility was broad and included many types of domestic U.S. organizations as well as certain non-U.S. entities. Eligible applicants included state, county, city/township, and special district governments; federally recognized tribal governments and other tribal organizations; public and private institutions of higher education; nonprofits both with and without 501(c)(3) status; for-profit organizations (including other than small businesses) and small businesses; public housing authorities/Indian housing authorities; and independent school districts. The eligibility information also explicitly included groups such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, foreign organizations (non-domestic entities), and eligible federal agencies. This wide eligibility suggests NIH intended to attract interdisciplinary teams and specialized capabilities, including chemistry, microbiology, genomics, and host-pathogen biology, regardless of whether they sit in traditional academic departments.

For applicants or researchers trying to understand what kind of project would have fit well, the best match would be work that uses chemistry to directly test biological function: for example, using chemical probes to perturb a pathway in a pathogen and measure effects on survival, virulence, or resistance-related phenotypes; mapping host-pathogen interactions using chemistry-enabled labeling or profiling; or employing chemical genetics strategies to connect a molecule’s activity to a specific protein target and then using that linkage to validate the target’s importance. The program’s language also points to value in annotating gene products, which often means taking proteins of unknown or uncertain function and using chemical perturbation and mechanistic experiments to assign them roles that matter in infection biology. The unifying idea is that strong target validation and functional annotation make subsequent screening and drug discovery efforts more efficient and less likely to fail due to weak biological rationale.

Administrative and access-related contact information in the source data directs users having trouble accessing the full announcement or linking to it to the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV, and an additional information link was provided via the NIH Grants Guide site (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-004.html).

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Oil Region National Heritage Area

Previous opportunity: NIH HMO Collaboratory Coordinating Center Limited Competition (U54)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AI 11 004

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AI 11 004) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 11 004", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.